Hiv testing and counselling for women attending child health clinics: An opportunity for entry to prevent mother-to-child transmission and hiv treatment. Author



Download 4.05 Mb.
Page19/47
Date31.01.2017
Size4.05 Mb.
#12892
1   ...   15   16   17   18   19   20   21   22   ...   47
Participants and approach:

Semistructured, in-depth, individual interviews of 26 AMPATH workers were conducted and recorded. Field notes from these interviews were generated by independent reviewers and subjected to close-reading qualitative analysis for themes.


Results:

The themes identified were as follows: creating effectively, connecting with others, making a difference, serving those in great need, providing comprehensive care to restore healthy lives, and growing as a person and a professional.


Conclusion:

Inspired personnel are among the critical assets of an effective program. Among the reasons for success of this HIV/AIDS program are a set of work values and motivations that would be helpful in any setting, but perhaps nowhere more critical than in the grueling work of making a complex program work spectacularly well in the challenging setting of a resource-poor country. Sometimes, even in the face of long odds, the human spirit prevails.



Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers.
Author: Iqbal, S. M.; Ball, T. B.; Kimani, J.; Kiama, P.; Thottingal, P.; Embree, J. E.; Fowke, K. R., and Plummer, F. A.
Source: J Infect Dis. 2005 Sep 1; 192(5):728-38.
Abstract: The initial site of exposure to human immunodeficiency virus (HIV)-1 during heterosexual transmission occurs in the genital tract. Although the majority of immunological studies have focused on the immune response to HIV-1 at the systemic level, our understanding of tissue-specific immunity is deficient. The goal of the present study was to characterize T cell populations found in the cervix of women shown to be resistant to infection by HIV-1. Levels of both systemic and cervical mucosal lymphocytes were compared between HIV-1-resistant, HIV-1-uninfected, and HIV-1-infected commercial sex workers (CSWs) as well as HIV-1-uninfected non-CSW control subjects at low risk for exposure. The HIV-1-resistant CSWs had increased cervical CD4+ and CD8+ T cell counts, compared with the HIV-1-uninfected CSWs; importantly, these increases were not reflected in the systemic lymphocyte compartment. There was a 2-fold increase in CD4+ T cell counts in the HIV-1-resistant CSWs, compared with both the HIV-1-infected and the HIV-1-uninfected CSWs. Expression of the HIV-1 coreceptors CCR5 and CXCR4 was also determined, and cytokine and beta chemokine levels in the genital mucosa were assessed. The HIV-1-resistant CSWs had a 10-fold increase in RANTES expression, compared with the HIV-1-uninfected CSWs. This is the first study to show elevated levels of beta chemokines and CD4+ T cells in the genital tracts of women who are exposed to HIV-1 and yet are uninfected.

HIV voluntary counselling and testing in Nakuru, Kenya: findings from a community survey.
Author: Irungu, T. K.; Varkey, P.; Cha, S., and Patterson, J. M.
Source: HIV Med. 2008 Feb; 9(2):111-7.
Abstract: Objectives:

HIV voluntary counselling and testing (VCT) is important for prevention, detection and treatment of HIV infection. A study was conducted to determine the extent of utilization of VCT, and to study the attitudes and preferences of the community regarding VCT.


Methods:

A total of 301 adults, aged 18-49 years, residing in Nakuru, Kenya were randomly selected using a two-stage sampling process. A self-administered questionnaire delivered during home visits was used to collect data over a 4-week period.


Results:

The majority of study participants (184 of 287; 64.1%) had never been tested for HIV; 77 (26.8%) had received VCT, and 26 (9.1%) had received HIV testing without counselling. A total of 219 (78.2%) of the 280 responding participants expressed readiness to have VCT. The majority of participants (216 of 296; 73%) preferred VCT, while 46 (15.5%) preferred testing without counselling. The majority (227; 76.7%) preferred couple testing and dedicated clinics and private doctors' offices as testing facilities. The choice of a nearby facility was ranked above the provision of anonymity by most participants (162 of 298; 54.4%; vice versa for 136 of 298; 45.6%).


Conclusions:

With HIV/AIDS continuing to be a major public health concern in Kenya, the issues surrounding acceptance and use of VCT need to be addressed. Enhancing community awareness of the benefits of early HIV diagnosis, providing couple-based VCT as an integral part of VCT and increasing access to VCT testing sites may enhance utilization of VCT.



Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
Author: Jaoko, W.; Nakwagala, F. N.; Anzala, O.; Manyonyi, G. O.; Birungi, J.; Nanvubya, A.; Bashir, F.; Bhatt, K.; Ogutu, H.; Wakasiaka, S.; Matu, L.; Waruingi, W.; Odada, J.; Oyaro, M.; Indangasi, J.; Ndinya-Achola, J.; Konde, C.; Mugisha, E.; Fast, P.; Schmidt, C.; Gilmour, J.; Tarragona, T.; Smith, C.; Barin, B.; Dally, L.; Johnson, B.; Muluubya, A.; Nielsen, L.; Hayes, P.; Boaz, M.; Hughes, P.; Hanke, T.; McMichael, A.; Bwayo, J., and Kaleebu, P.
Source: Vaccine. 2008 May 23; 26(22):2788-95.
Abstract: The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and Uganda. Both vaccines, expressing HIV-1 subtype A gag p24/p17 and a string of CD8 T-cell epitopes (HIVA), were generally safe and well-tolerated. At the dosage levels and intervals tested, the percentage of vaccine recipients with HIV-1-specific cell-mediated immune responses, assessed by a validated ex vivo interferon gamma (IFN-gamma) ELISPOT assay and Cytokine Flow Cytometry (CFC), did not significantly differ from placebo recipients. These trials demonstrated the feasibility of conducting high-quality Phase 1 trials in Africa.
Cost effectiveness of couple counselling to enhance infant HIV-1 prevention.
Author: John, F. N.; Farquhar, C.; Kiarie, J. N.; Kabura, M. N., and John-Stewart, G. C.
Source: Int J STD AIDS. 2008 Jun; 19(6):406-9.
Abstract: Data collected in the years 2001--2003 from an antenatal clinic in Nairobi, Kenya, were used to assess the benefit of couple counselling and test it as a way of increasing the uptake of interventions in the prevention of mother-to-child transmission of HIV-1. Among 2833 women enrolled, 311 (11%) received couple pretest counselling and 2100 (74%) accepted HIV-1 testing. Among those tested 314 (15%) were HIV-1 seropositive. We incorporated these and other data from the cohort study into a spreadsheet-based model and costs associated with couple counselling were compared with individual counselling in a theoretical cohort of 10,000 women. Voluntary couple counselling and testing (VCT), although more expensive, averted a greater number of infant infections when compared with individual VCT. Cost per disability-adjusted life year was similar to that of individual VCT. Sensitivity analyses found that couple VCT was more cost-effective in scenarios with increased uptake of couple counselling and higher HIV-1 prevalence.

Risk factors for HIV infection in a national adult population: evidence from the 2003 Kenya Demographic and Health Survey.
Author: Johnson, K. and Way, A.
Source: J Acquir Immune Defic Syndr. 2006 Aug 15; 42(5):627-36.
Abstract: Objective:

To study demographic, social, behavioral, and biological variables as risk factors for HIV infection among men and women in Kenya.


Methods:

Data from the cross-sectional, population-based 2003 Kenya Demographic and Health Survey were used. During the course of survey fieldwork, 3,273 women aged 15 to 49 years and 2,941 men aged 15 to 54 years gave consent to have a few drops of blood taken for anonymous testing. HIV serostatus data for men and women were analyzed for their relationships to key characteristics using bivariate and multivariate techniques to determine factors associated with being HIV-positive.


Results:

National HIV prevalence in Kenya was found to be 6.7%. In the analysis of the study sample, uncircumcised men were 4 times more likely to be HIV-positive than those who were not. Compared with nonpolygynously married women, widowed women (odds ratio [OR] = 10.9), divorced women (OR = 2.3), and women who were 1 of 3 or more wives (OR = 3.4) were all at higher risk for being HIV-positive. Both men and women from Nyanza province were at a significantly higher risk for infection with HIV (OR = 2.9 and 2.3, respectively) than were the men and women from Nairobi. Men aged 35 to 44 years had the highest risk of being HIV-positive, whereas the ages of highest risk for women were 25 to 29 years. Increased wealth was positively related to risk for HIV: the wealthiest women were 2.6 times more likely than the poorest women to be HIV-positive. A key finding was that both men and women who considered themselves to be at low risk for contracting HIV were, in fact, the most likely to be HIV-positive.


Conclusions:

This analysis demonstrates that HIV is a multidimensional epidemic, with demographic, residential, social, biological, and behavioral factors all exerting influence on individual probability of becoming infected with HIV. Although all of these factors contribute to the risk profile for a given individual, the results suggest that differences in biological factors such as circumcision and sexually transmitted infections may be more important in assessing risk for HIV than differences in sexual behavior.



The impact of maternal HIV status on infant feeding patterns in Nakuru, Kenya.
Author: Kamau-Mbuthia, E.; Elmadfa, I., and Mwonya, R.
Source: J Hum Lact. 2008 Feb; 24(1):34-41.
Abstract: The aim of the study was to assess the impact of maternal HIV status on infant feeding patterns. Two hundred eighty mothers (205 HIV uninfected, 75 infected) and their infants were recruited from the Provincial General Hospital, Nakuru, Kenya, from delivery and were followed for 14 weeks. From the feeding patterns, HIV-infected mothers were more likely to exclusively breastfeed in week 1 than HIV-uninfected mothers (71.7% vs 56.3%, P = .001), but there were no differences by week 14 (9.8% vs 4.8% P = .212). Mixed feeding increased for both groups from weeks 1 to 14. In multivariate logistic regression analysis, maternal age (younger mothers, P < .05) was associated with exclusive breastfeeding in the 6th week and infant birth weight (> mean birth weight, P < .05) in the 10th week. The results indicate a need to reassess adherence to infant feeding recommendations irrespective of maternal HIV status and also the infant feeding counseling process in the hospital. J Hum Lact . 24(1):34-41.

Anti-HIV-1 activities in extracts from some medicinal plants as assessed in an in vitro biochemical HIV-1 reverse transcriptase assay.
Author: Kanyara, J. N. and Njagi, E. N.
Source: Phytother Res. 2005 Apr; 19(4):287-90.
Abstract: An in vitro HIV-1 reverse transcriptase (RT) assay was used for screening of anti-HIV activity of extracts obtained from some Kenyan medicinal plants. The assay utilises [3H]-methyl thymidine triphosphate (dTTP) as the enzyme substrate and polyadenylic acid.oligodeoxythymidylic acid [poly(rA).p(dT)(12-18)] as the template-primer dimmer. This assay was optimised and standardised with respect to the various experimental parameters in a microtiter plate methodology. The assay was then applied to test for potential antiviral activities of several Kenyan medicinal plant extracts and the concentrations producing 50% inhibition (IC50) of the HIV-1 RT were determined. This assay is described in this report and results obtained with some of the extracts are presented.

Knowledge, attitude and practice towards HIV/AIDS in a rural Kenyan community.
Author: Karama, M.; Yamamoto, T.; Shimada, M.; Orago, S. S., and Moji, K.
Source: J Biosoc Sci. 2006 Jul; 38(4):481-90.
Abstract: The aim of this research was to explore people's knowledge, attitude, behaviour and practice towards HIV/AIDS and sexual activity in rural Kenya, where HIV is widespread. The study community was located in south-eastern Kenya, 50 km north of Mombassa, and had an estimated population of 1500. Subjects aged between 16 and 49 were recruited using a stratified cluster-sampling method and they completed self-administered questionnaires.Almost all respondents knew the word 'IV' Around 50% knew of a person living with HIV. About 80% gave 'death' or 'fear' as words representing their image of AIDS. With regard to sexual activity, the distribution of answers to the question 'how many partners have you ever had in your life' was bimodal in males but had only one peak in females, indicating that some men have a large number of sexual partners in their lifetime. First sexual intercourse was at around 12-13 years for both sexes, but female teenagers were more sexually experienced than their male counterparts.


Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya.
Author: Karcher, H.; Omondi, A.; Odera, J.; Kunz, A., and Harms, G.
Source: Trop Med Int Health. 2007 May; 12(5):687-94.
Abstract: Objectives:

To evaluate risk factors for treatment denial and loss to follow-up in an antiretroviral treatment (ART) cohort in a rural African setting in western Kenya.


Method:

Sociodemographic and clinical data of patients enrolled in an ART cohort were collected within 18 months of an observational longitudinal study and analysed by logistic and Cox regression models.


Results:

Of 159 patients with treatment indication 35 (22%) never started ART. Pregnancy [adjusted odds ratio (AOR) 3.60, 95% confidence interval (CI) 1.10-11.8; P = 0.035] and lower level of education (AOR 3.80, 95% CI 1.14-12.7; P = 0.03) were independently associated with treatment denial. The incidence of total loss of patients under therapy was 43.2 per 100 person years (pys) (mortality rate 19.2 per 100 pys plus drop out rate 24 per 100 pys). Older age [adjusted hazard ratio (AHR) 1.06, 95% CI 1.01-1.12; P = 0.04], AIDS before starting treatment (AHR 5.83, 95% CI 1.15-29.5; P = 0.03) and incomplete adherence to treatment (AHR 1.05, 95% CI 1.03-1.07; P < 0.001) were independent risk factors for death. Incomplete adherence also independently predicted drop out because of other reasons (AHR 1.06, 95% CI 1.04-1.09; P < 0.001).


Conclusion:

Pregnancy and lower level of education, higher age, advanced AIDS stage and impaired compliance to ART were identified as risk factors for treatment denial and death, respectively. Adequate counselling strategies for patients with these characteristics could help to improve adherence and outcome of treatment programmes in resource-limited settings.



Prevalence of HCV and HCV/HIV co-infection among in-patients at the Kenyatta National Hospital.
Author: Karuru, J. W.; Lule, G. N.; Joshi, M., and Anzala, O.
Source: East Afr Med J. 2005 Apr; 82(4):170-2.
Abstract: Objective:

To determine the prevalence of HCV and HCV/HIV co-infection among medical in-patients at the Kenyatta National Hospital. DESIGN: Prospective cross-sectional descriptive study.


Setting:

Kenyatta National Hospital, a tertiary referral and teaching hospital, in-patient department


Subjects:

HIV/AIDS and HIV negative in-patients at KNH medical wards. RESULTS: Among 458 HIV/AIDS medical in-patients, the prevalence of HCV was 3.7% while in the 518 HIV negative patients, it was 4.4%. The prevalence of co-infection with HCV and HIV was 3.7%. The incidence of risk factors in persons with HCV and/or HIV infection(s) was low.


Conclusion:

This study found the prevalence of HCV infection among medical in-patients to be similar in HIV positive and HIV negative group of patients. The co-infection rates were low, as were the risk factors for transmission of these infections.



Prevalent herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to multiple sexually transmitted infections.
Author: Kaul, R.; Nagelkerke, N. J.; Kimani, J.; Ngugi, E.; Bwayo, J. J.; Macdonald, K. S.; Rebbaprgada, A.; Fonck, K.; Temmerman, M.; Ronald, A. R., and Moses, S.
Source: J Infect Dis. 2007 Dec 1; 196(11):1692-7.
Abstract: Background:

Prevalent herpes simplex virus type 2 (HSV-2) infection increases human immunodeficiency virus acquisition. We hypothesized that HSV-2 infection might also predispose individuals to acquire other common sexually transmitted infections (STIs).


Methods:

We studied the association between prevalent HSV-2 infection and STI incidence in a prospective, randomized trial of periodic STI therapy among Kenyan female sex workers. Participants were screened monthly for infection with Neisseria gonorrhoeae and Chlamydia trachomatis, and at least every 6 months for bacterial vaginosis (BV) and infection with Treponema pallidum, Trichomonas vaginalis, and/or HSV-2.


Results:

Increased prevalence of HSV-2 infection and increased prevalence of BV were each associated with the other; the direction of causality could not be determined. After stratifying for sexual risk-taking, BV status, and antibiotic use, prevalent HSV-2 infection remained associated with an increased incidence of infection with N. gonorrhoeae (incidence rate ratio [IRR], 4.3 [95% confidence interval {CI}, 1.5-12.2]), T. vaginalis (IRR, 2.3 [95% CI, 1.3-4.2]), and syphilis (IRR, 4.7 [95% CI, 1.1-19.9]). BV was associated with increased rates of infection with C. trachomatis (IRR, 2.1 [95% CI, 1.1-3.8]) and T. vaginalis (IRR, 8.0 [95% CI, 3.2-19.8]).


Conclusion:

Increased prevalences of HSV-2 infection and BV were associated with each other and also associated with enhanced susceptibility to an overlapping spectrum of other STIs. Demonstration of causality will require clinical trials that suppress HSV-2 infection, BV, or both.



Drug evaluation: DNA/MVA prime-boost HIV vaccine.
Author: Kent, S.; De Rose, R., and Rollman, E.
Source: Curr Opin Investig Drugs. 2007 Feb; 8(2):159-67.
Abstract: Oxford University and Nairobi University are jointly developing a HIVA.DNA/modified vaccinia Ankara (MVA) prime-boost vaccine for the potential prevention of infection with HIV subtype A. The vaccination strategy consists of priming with a DNA vaccine made from HIV-1 clade A gag p24/p17 consensus sequence (pTHr.HIVA) then boosting with a MVA virus expressing HIVA (MVA.HIVA). Phase II clinical trials of the vaccine are underway in Kenya and the UK.

Rapid Identification of Infants for Antiretroviral Therapy in a Resource Poor Setting: The Kenya Experience.
Author: Khamadi, S.; Okoth, V.; Lihana, R.; Nabwera, J.; Hungu, J.; Okoth, F.; Lubano, K., and Mwau, M.
Source: J Trop Pediatr. 2008 May 29.
Abstract: In Kenya, HIV diagnosis is not routinely carried out in infants, and yet rapid diagnosis could improve access to lifesaving interventions. A cheap and readily accessible service can resolve this problem, if feasible. In this pilot study the feasibility and costs of provision of an infant HIV diagnosis service in Kenya are evaluated. Dried blood spots (DBS) were collected from infants exposed to HIV, sent to a central testing laboratory and tested using the Roche Amplicor v. 1.5 DNA PCR kit. The results were then dispatched to health facilities within a week. A total of 15.4% of the samples tested HIV+ despite the widespread access to prevention of mother to child transmission (PMTCT) programs in Kenya. The cost per test at 21.50 USD is prohibitive and will limit access to diagnosis. It remains to be seen whether the increase in testing will immediately lead to an increase in access to antiretroviral therapy (ART) services for infants.

HIV type 1 subtypes in circulation in northern Kenya.
Author: Khamadi, S. A.; Ochieng, W.; Lihana, R. W.; Kinyua, J.; Muriuki, J.; Mwangi, J.; Lwembe, R.; Kiptoo, M.; Osman, S.; Lagat, N.; Pelle, R.; Muigai, A.; Carter, J. Y.; Oishi, I.; Ichimura, H.; Mwaniki, D. L.; Okoth, F. A.; Mpoke, S., and Songok, E. M.
Source: AIDS Res Hum Retroviruses. 2005 Sep; 21(9):810-4.
Abstract: The genetic subtypes of HIV-1 circulating in northern Kenya have not been characterized. Here we report the partial sequencing and analysis of samples collected in the years 2003 and 2004 from 72 HIV-1-positive patients in northern Kenya, which borders Ethiopia50% were subtype A, 39% subtype C, and 11% subtype D. This shows that in the northern border region of Kenya subtypes A and C are the dominant HIV-1 subtypes in circulation. Ethiopia is dominated mainly by HIV-1 subtype C, which incidentally is the dominant subtype in the town of Moyale, which borders Ethiopia. These results show that cross-border movements play an important role in the circulation of subtypes in Northern Kenya., Somalia, and Sudan. From the analysis of partial env sequences, it was determined that

Genetic analysis of HIV-1 subtypes in Nairobi, Kenya.
Author: Khoja, S.; Ojwang, P.; Khan, S.; Okinda, N.; Harania, R., and Ali, S.
Source: PLoS ONE. 2008; 3(9):e3191.
Abstract: Background:

Genetic analysis of a viral infection helps in following its spread in a given population, in tracking the routes of infection and, where applicable, in vaccine design. Additionally, sequence analysis of the viral genome provides information about patterns of genetic divergence that may have occurred during viral evolution.


Objective:

In this study we have analyzed the subtypes of Human Immunodeficiency Virus -1 (HIV-1) circulating in a diverse sample population of Nairobi, Kenya.


Methodology:

69 blood samples were collected from a diverse subject population attending the Aga Khan University Hospital in Nairobi, Kenya. Total DNA was extracted from peripheral blood mononuclear cells (PBMCs), and used in a Polymerase Chain Reaction (PCR) to amplify the HIV gag gene. The PCR amplimers were partially sequenced, and alignment and phylogenetic analysis of these sequences was performed using the Los Alamos HIV Database.


Results:

Blood samples from 69 HIV-1 infected subjects from varying ethnic backgrounds were analyzed. Sequence alignment and phylogenetic analysis showed 39 isolates to be subtype A, 13 subtype D, 7 subtype C, 3 subtype AD and CRF01_AE, 2 subtype G and 1 subtype AC and 1 AG. Deeper phylogenetic analysis revealed HIV subtype A sequences to be highly divergent as compared to subtypes D and C.


Conclusion:

Our analysis indicates that HIV-1 subtypes in the Nairobi province of Kenya are dominated by a genetically diverse clade A. Additionally, the prevalence of highly divergent, complex subtypes, intersubtypes, and the recombinant forms indicates viral mixing in Kenyan population, possibly as a result of dual infections.



Reference ranges for the clinical laboratory derived from a rural population in Kericho, Kenya.
Author: Kibaya, R. S.; Bautista, C. T.; Sawe, F. K.; Shaffer, D. N.; Sateren, W. B.; Scott, P. T.; Michael, N. L.; Robb, M. L.; Birx, D. L., and de Souza, M. S.
Source: PLoS ONE. 2008; 3(10):e3327.
Abstract: The conduct of Phase I/II HIV vaccine trials internationally necessitates the development of region-specific clinical reference ranges for trial enrollment and participant monitoring. A population based cohort of adults in Kericho, Kenya, a potential vaccine trial site, allowed development of clinical laboratory reference ranges. Lymphocyte immunophenotyping was performed on 1293 HIV seronegative study participants. Hematology and clinical chemistry were performed on up to 1541 cohort enrollees. The ratio of males to females was 1.9:1. Means, medians and 95% reference ranges were calculated and compared with those from other nations. The median CD4+ T cell count for the group was 810 cells/microl. There were significant gender differences for both red and white blood cell parameters. Kenyan subjects had lower median hemoglobin concentrations (9.5 g/dL; range 6.7-11.1) and neutrophil counts (1850 cells/microl; range 914-4715) compared to North Americans. Kenyan clinical chemistry reference ranges were comparable to those from the USA, with the exception of the upper limits for bilirubin and blood urea nitrogen, which were 2.3-fold higher and 1.5-fold lower, respectively. This study is the first to assess clinical reference ranges for a highland community in Kenya and highlights the need to define clinical laboratory ranges from the national community not only for clinical research but also care and treatment.


Download 4.05 Mb.

Share with your friends:
1   ...   15   16   17   18   19   20   21   22   ...   47




The database is protected by copyright ©ininet.org 2024
send message

    Main page